Article Text

PDF

Comparison of Acceleration Algorithms in Whole-Heart Four
028 Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping
  1. Ana Martinez-Naharro1,
  2. Daniel S Knight1,
  3. Tushar Kotecha1,
  4. Rohin Francis1,
  5. Giulia Zumbo1,
  6. Thomas A Treibel2,
  7. Jannike Nickander3,
  8. Raquel Themudo3,
  9. Julian D Gillmore1,
  10. Martin Ugander3,
  11. James C Moon2,
  12. Hui Xue4,
  13. Peter Kellman4,
  14. Philip N Hawkins1,
  15. Marianna Fontana1
  1. 1National Amyloidosis Centre, University College London, Royal Free Hospital, London, UK
  2. 2Karolinska Insitutet, Sweden
  3. 3Barts Heart Centre, West Smithfield, London, UK
  4. 4National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA

Abstract

Background Cardiac involvement is the main driver of outcome in systemic amyloidosis, but the relationship between amyloid deposits and cellular injury is not well understood. The simple explanation of physical, mechanical replacement of parenchymal tissue seems insufficient, and preliminary studies support the hypothesis that myocardial hypoperfusion could contribute to cell damage in amyloidosis. The aim of this study was: 1) To assess feasibility of fully automated pixel-wise rest myocardial blood flow (MBF) mapping in cardiac amyloidosis during routine clinical scans; 2) To assess the prevalence of myocardial hypoperfusion and correlation with amyloid deposits and disease severity.

Methods Patients (n=56) with systemic amyloidosis and healthy volunteers (n=16) were recruited. All subjects underwent CMR at 1.5T (Siemens) with standard SSFP cine imaging, Phase Sensitive Inversion Recovery Reconstruction Late Gadolinium Enhancement (PSIR-LGE), T1 mapping, Extracellular Volume (ECV) mapping and rest MBF mapping.

Results The pixel-wise MBF maps for all slices were generated automatically in all patients within 2.5 min after image acquisition. Myocardial perfusion was globally reduced in patients with cardiac amyloidosis compared to healthy volunteers (0.66±0.26 ml/min/g vs 0.84±0.19 ml/min/g, p<0.05). Myocardial perfusion inversely correlated with amyloid burden measured as extracellular volume fraction (r=−0.46, p<0.001) (figure 1) and with the transmurality of LGE (no LGE 0.88±0.18 ml/min/g, subendocardial LGE 0.73±0.28 ml/min/g and transmural LGE 0.58±0.20 ml/min/g, p<0.01) (figure 2). There was a correlation between myocardial perfusion and markers of systolic dysfunction (EF, r=0.39, p<0.01) as well as blood biomarkers (NT-proBNP, r=−0.41, p<0.01 and Troponin T, r=−0.41, p<0.01), current reference prognostic markers in cardiac amyloidosis. There was no significant correlation between myocardial perfusion and native T1 values (r=−0.07, p=0.59).

Conclusions Myocardial perfusion can be measured in cardiac amyloidosis during routine clinical scans with fully automated MBF mapping. Myocardial hypoperfusion at rest is highly prevalent in subjects with cardiac amyloidosis, and correlates with the degree of amyloid infiltration and disease severity.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.